CONTEXT: Highly active antiretroviral therapy (HAART) is often withheld from injection drug users (IDUs) infected with the human immunodeficiency virus (HIV) based on the belief that their unstable lifestyles may predetermine a markedly inferior outcome with HAART. However, long-term evaluations of HIV treatment outcomes among IDUs in comparison with other risk groups are not available. OBJECTIVE: To compare survival rates among HIV-infected patients initiating HAART with and without a history of injection drug use. DESIGN, SETTING, AND PATIENTS: Population-based, prospective cohort study (HAART Observational Medical Evaluation and Research [HOMER]) of 3116 antiretroviral-naive HIV-infected patients in a province-wide HIV/AIDS treatment program in British Columbia, Canada. Of the 3116 patients, 915 were IDUs (29.4%), 579 were female (18.6%), and the median age was 39.4 years (interquartile range, 33.3-46.4 years). Treatment with HAART was initiated between August 1, 1996, and June 30, 2006. The median duration of follow-up was 5.3 years (interquartile range, 2.8-8.3 years) for IDUs and 4.3 years (interquartile range, 2.0-7.6 years) for non-IDUs. Patients were followed up until June 30, 2007. Data were analyzed between November 1, 2007, and May 26, 2008. MAIN OUTCOME MEASURE: All-cause mortality. RESULTS: Overall, 622 individuals died (20.0%) during the study period (232 IDUs and 390 non-IDUs), for a crude mortality rate of 20.0% (95% confidence interval [CI], 18.4%-21.5%). At 84 months after the initiation of HAART, the product limit estimate of the cumulative all-cause mortality rate was similar between the 915 IDUs (26.5%; 95% CI, 23.2%-29.8%) and 2201 non-IDUs (21.6%; 95% CI, 16.9%-26.2%) (Wilcoxon P = .47). In multivariate time-updated Cox regression, the hazard ratio of mortality was similar between IDUs and non-IDUs (1.09; 95% CI, 0.92-1.29). CONCLUSION: In this study population, injection drug use was not associated with decreased survival among HIV-infected patients initiating HAART.
CONTEXT: Highly active antiretroviral therapy (HAART) is often withheld from injection drug users (IDUs) infected with the human immunodeficiency virus (HIV) based on the belief that their unstable lifestyles may predetermine a markedly inferior outcome with HAART. However, long-term evaluations of HIV treatment outcomes among IDUs in comparison with other risk groups are not available. OBJECTIVE: To compare survival rates among HIV-infectedpatients initiating HAART with and without a history of injection drug use. DESIGN, SETTING, AND PATIENTS: Population-based, prospective cohort study (HAART Observational Medical Evaluation and Research [HOMER]) of 3116 antiretroviral-naive HIV-infectedpatients in a province-wide HIV/AIDS treatment program in British Columbia, Canada. Of the 3116 patients, 915 were IDUs (29.4%), 579 were female (18.6%), and the median age was 39.4 years (interquartile range, 33.3-46.4 years). Treatment with HAART was initiated between August 1, 1996, and June 30, 2006. The median duration of follow-up was 5.3 years (interquartile range, 2.8-8.3 years) for IDUs and 4.3 years (interquartile range, 2.0-7.6 years) for non-IDUs. Patients were followed up until June 30, 2007. Data were analyzed between November 1, 2007, and May 26, 2008. MAIN OUTCOME MEASURE: All-cause mortality. RESULTS: Overall, 622 individuals died (20.0%) during the study period (232 IDUs and 390 non-IDUs), for a crude mortality rate of 20.0% (95% confidence interval [CI], 18.4%-21.5%). At 84 months after the initiation of HAART, the product limit estimate of the cumulative all-cause mortality rate was similar between the 915 IDUs (26.5%; 95% CI, 23.2%-29.8%) and 2201 non-IDUs (21.6%; 95% CI, 16.9%-26.2%) (Wilcoxon P = .47). In multivariate time-updated Cox regression, the hazard ratio of mortality was similar between IDUs and non-IDUs (1.09; 95% CI, 0.92-1.29). CONCLUSION: In this study population, injection drug use was not associated with decreased survival among HIV-infectedpatients initiating HAART.
Authors: M-J Milloy; Thomas Kerr; David R Bangsberg; Jane Buxton; Surita Parashar; Silvia Guillemi; Julio Montaner; Evan Wood Journal: AIDS Patient Care STDS Date: 2011-11-22 Impact factor: 5.078
Authors: Scott E Hadland; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; Robert S Hogg; Julio S Montaner; Evan Wood Journal: AIDS Patient Care STDS Date: 2012-03-19 Impact factor: 5.078
Authors: James C M Brust; Alain H Litwin; Karina M Berg; Xuan Li; Moonseong Heo; Julia H Arnsten Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Sasha Uhlmann; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; David Marsh; Robert S Hogg; Julio S G Montaner; Evan Wood Journal: Addiction Date: 2010-03-10 Impact factor: 6.526
Authors: Robert A Bonacci; Katherine Frasca; Lyles Swift; Daohang Sha; Warren B Bilker; Laura Bamford; Baligh R Yehia; Robert Gross Journal: AIDS Behav Date: 2016-05
Authors: Keri L Calkins; Catherine R Lesko; Geetanjali Chander; Richard D Moore; Bryan Lau Journal: J Acquir Immune Defic Syndr Date: 2018-03-01 Impact factor: 3.731
Authors: Lianping Ti; M-J Milloy; Kate Shannon; Annick Simo; Robert S Hogg; Sylvia Guillemi; Julio Montaner; Thomas Kerr; Evan Wood Journal: Sex Transm Infect Date: 2014-02-12 Impact factor: 3.519
Authors: Bohdan Nosyk; Jeong E Min; Guillaume Colley; Viviane D Lima; Benita Yip; M-J S Milloy; Evan Wood; Julio S G Montaner Journal: AIDS Date: 2015-05-15 Impact factor: 4.177